Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (August 2021)

36 slides from Kazia Therapeutics's investor presentation, Aug 16, 2021

  1. Slide 1: Kazia Provides Updated Non-Confidential Corporate Presentation (ASX release)

    ASX RELEASE 16 August 2021 KAZIA PROVIDES UPDATED NON-CONFIDENTIAL CORPORATE PRESENTATION Sydney, 16 August 2021 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an updated non- confidential corporate presentation. The present

  2. Slide 2: A Diversified, Clinical-Stage Oncology Drug Development Company

    A Diversified, Clinical-Stage Oncology Drug Development Company Corporate Introduction August 2021 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state

  4. Slide 4: Company Overview: An oncology drug-development company

    Company Overview An oncology drug-development company Lead Program in Phase III for Diversified Clinical-Stage Strong Corporate Glioblastoma Pipeline Fundamentals Paxalisib EVT801 • Listed on ASX (KZA) and on • Brain-penetrant PI3K / mTOR • First-in-class selective VEGFR3 NASDAQ (KZIA) inhibitor, in

  5. Slide 5: Corporate History

    Corporate History Kazia has shown remarkable growth in five years October 2016 May 2018 November 2019 January 2021 April 2021 Paxalisib (then Phase II clinical First interim Paxalisib begins EVT801 licensed in known as GDC- study of paxalisib efficacy date from recruitment to GBM from Evotec SE 0084

  6. Slide 6: Pipeline: Two world-class assets in clinical trials by end CY2021

    Pipeline Two world-class assets in clinical trials by end CY2021 licensed from: Paxalisib (GDC-0084) Small molecule, brain-penetrant inhibitor of PI3K / mTOR PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Glioblastoma Most common primary brain cancer DIPG Highly aggressive childhood brain cancer Primary CN

  7. Slide 7: Operating Model: In-licensing advanced assets drives earlier value realization

    Operating Model In-licensing advanced assets drives earlier value realization A Proven Strategy Jun 2010 – licensed niraparib from Merck Mar 2017 – Zejula® (niraparib) approved by FDA License under- Develop value Partner for Dec 2018 – Tesaro acquired by GSK valued assets through late-stage from lar

  8. Slide 8: Leadership

    Leadership Extensive international drug development experience Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech Bryce Carmine Dr Kar

  9. Slide 9: Financial Metrics

    as at 30 JUN 21 Financial Metrics Value-driving news flow for investors 16.00 Share Price (US$) KZIA Market Capitalisation US$ 130M 14.00 Listing ASX (primary) KZA 12.00 NASDAQ (ADSs @ 1:10 ratio) KZIA Shares on Issue 130M 10.00 Balance Sheet US$ 8.00 Cash (at 30 Jun 21) $20.3M Monthly Burn Rate ~$1

  10. Slide 10: CY2021 Milestones and Newsflow

    CY2021 Milestones and Newsflow Multiple catalysts across two clinical programs Commence of recruitment to GBM AGILE pivotal study for paxalisib January 2021 ✓ Out-license of Cantrixil legacy asset to Oasmia Pharmaceutical March 2021 ✓ Partnership for paxalisib in Greater China with Simcere Pharmaceu

  11. Slide 11: Investment Rationale

    Investment Rationale A compelling corporate story High-Quality Valuable Efficient, Well- Rapid Path to Pipeline Commercial Funded Business Value Realisation Opportunities • Pipeline assets • Glioblastoma alone is • ~US$ 20M cash at 30 • Paxalisib potentially invented by a ~US$ 1.5B market June 2021;

  12. Slide 12: Paxalisib: Brain Cancer, Phase III

    Paxalisib Brain Cancer Phase III 10

  13. Slide 13: Treatment of brain cancer has improved little in recent decades

    Treatment of brain cancer has improved little in recent decades, unlike other cancers Lung 1990s 2000s 2010s Cancer Brain Cancer 1990s 2000s 2010s (glioblastoma) 11

  14. Slide 14: Paxalisib was designed to overcome key challenges in brain cancer treatment

    Paxalisib was designed specifically to overcome key challenges in the treatment of brain cancer Crosses Blood-Brain Barrier Oral Presentation Most anti-cancer drugs are not brain penetrant 15mg capsule, taken once daily; no significant food effect Targets PI3K / mTOR Pathway Strong IP Protection Com

  15. Slide 15: Glioblastoma is the most common and aggressive primary brain cancer

    Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear Any age, No clear but most improvement in cause common in prognosis for Breast or strong risk factors 60s 20 years 14 million cancer cases per annum Colon 3-4 months 12-15 Five-year survival Prostate

  16. Slide 16: Temozolomide is the only FDA-approved drug for GBM; ineffective in ~65%

    Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond Paxalisib is being developed prima

  17. Slide 17: The PI3K / Akt / mTOR pathway is a critical signalling mechanism

    The PI3K / Akt / mTOR pathway is a critical signalling mechanism for many tumor types Growth factor receptors Comparative Potency vs Other PI3K Inhibitors (e.g. EGFR, HER2) IC50 (nM) Idealisib (Gilead) p110a p110b p110g p110d mTORC PI3K 1/2 Alpelisib (Novartis) Paxalisib 2 46 10 3 70 Idelalisib 820

  18. Slide 18: Paxalisib is unique among PI3K inhibitors in crossing the blood-brain barrier

    The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig Aliqopa Copiktra Piqray Ukoniq paxalisib (idelalisib) (copanlisib) (duvelisib) (alpelisib) (umbralasib) FDA Approved FDA Approved FDA Approved FDA Approved FDA Approved In pi

  19. Slide 19: Paxalisib shows single-agent activity in preclinical glioblastoma models

    Paxalisib shows convincing single-agent activity in preclinical models of glioblastoma Illustrative Dose-Dependent Activity in U87 Model General Findings Tumor Volume (mm3) Widespread activity in a range of PDX Vehicle models; appears unaffected by MGMT 0.03 mg/kg promotor status 0.45 mg/kg 2.2 mg/k

  20. Slide 20: Latest phase II data compares well to temozolomide

    INTERIM DATA Latest phase II data compares well to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Paxalisib 8.4 months Paxalisib 17.5 months Median PFS Median OS Temozolomide 5.3 months Temozolomide 12.7 months (existi

  21. Slide 21: Toxicities are generally mild to moderate and manageable

    INTERIM DATA Toxicities are generally mild to moderate, entirely reversible, and manageable with readily-available therapies Number of Patients at 60mg (n=24) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥2 patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Rash 4 6 7 17 (71%) F

  22. Slide 22: Nine clinical studies are active across multiple forms of brain cancer

    Nine clinical studies are active across multiple forms of brain cancer Registration Indication Phase N Status Sponsor Primary Brain Cancer NCT03522298 Glioblastoma II 30 Follow-up Glioblastoma TBD II 33-60 Start-up (combination with ketogenic diet) Glioblastoma Up to 200 on NCT03970447 II / III Recr

  23. Slide 23: GBM AGILE international pivotal study is underway

    GBM AGILE international pivotal study is underway, and is expected to provide the basis for regulatory approval Key Points 3 • A ‘platform study’, run Regorafenib Economies of scale independently of individual due to multiple companies, designed to expedite participating drugs allows for large site

  24. Slide 24: Commercial opportunity is substantial, with one partnership in place

    Commercial opportunity is substantial, with one commercial partnership already in place Opportunities ‘Blue Sky’ Other Cancers with PI3K Partnership with Simcere Pharmaceutical for Greater Dysregulation China signed in March 2021 (e.g. breast, lung) Simcere will develop and commercialise paxalisib f

  25. Slide 25: Key Points

    Key Points • Well-understood mechanism (PI3K inhibition) but unique differentiating feature (brain penetration) • Positive phase II data in glioblastoma, supported by very strong preclinical package and positive phase I data • Fully-funded international registration study underway with support of FD

  26. Slide 26: EVT801: Solid Tumors, Pre-Phase I

    EVT801 Solid Tumors Pre-Phase I 24

  27. Slide 27: Targeting angiogenesis is a well-established approach in cancer treatment

    Targeting angiogenesis is a well-established approach in the treatment of cancer Product Company Target Indications Annual Sales (US$)* • Colorectal cancer • Lung cancer VEGF-A • Breast cancer $7 billion • Other cancers VEGFR • Hepatocellular carcinoma PDGFR • Renal call carcinoma $1 billion RAF kin

  28. Slide 28: Angiogenesis inhibitors are limited by several key challenges

    Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges 1 Angiogenesis inhibitors work by reducing Tumor Hypoxia the formation of new blood vessels around the tumor, starving it of vital Sustained tumor hypoxia activates adaptive mechanisms, Limited nutrients nee

  29. Slide 29: EVT801 is a selective VEGFR inhibitor, inhibiting lymphangiogenesis

    EVT801 is a selective VEGFR inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Oral Presentation Expected to minimise off-target toxicities Administered by mouth once or twice daily Inhibits lymphangiogenesis Strong IP Protection Compos

  30. Slide 30: EVT801 selectively inhibits VEGFR3

    EVT801 selectively inhibits VEGFR3 Avastin Lucentis (bevacizumab) (ranibizumab) VEGF-B VEGF-A VEGF-D VEGF-E VEGF-C Sutent EVT801 (sunitinib) VEGFR1 VEGFR2 VEGFR3 Nexavar (sorafenib) Inlyta Cell Survival Signal Modulation Angiogenesis (axitinib) Votrient Lymphangio- Vasculogenesis genesis (panzopanib

  31. Slide 31: EVT801 is expected to have three primary mechanisms of action

    EVT801 is expected to have three primary mechanisms of action Tumor Killing 1 Direct effect on VEGFR3-expressing tumor cells (typically from endothelial origin, e.g. sarcoma) 3 3 Increase in Anti-Tumor Immune Activity 2 Increased infiltration of effector T-cells, and reduction in immunosuppressive 1

  32. Slide 32: Preclinical data confirms activity of EVT801 (1/2)

    Preclinical data confirms activity of EVT801 (1/2) Dramatic single-agent activity in DEN-induced HCC model Tumor Growth Metastasis Experimental Methods Total Tumor Volume Number of Tumors in the Liver • Syngeneic mouse model • Hepatocellular carcinoma chemically 85% reduction 50% reduction induced w

  33. Slide 33: Preclinical data confirms activity of EVT801 (2/2)

    Preclinical data confirms activity of EVT801 (2/2) Synergistic activity in combination with anti-CTLA4 mAb Tumor Volume (mm3) Experimental Methods 500 • Orthotopic mouse model Vehicle • 4T1 tumor cells inoculated in BALB/c EVT801 mice (mammary fat pad) 400 anti-CTLA4 • Treatment with EVT801 on D7-D2

  34. Slide 34: Kazia plans to commence a phase I clinical trial in CY2021

    Kazia plans to commence a phase I clinical trial in CY2021 Up to 90 patients with advanced Current Status solid tumors, resistant to existing • Investigational product therapies manufactured and ready to ship ✓ Endpoints will include safety and • Draft clinical trial protocol prepared tolerability,

  35. Slide 35: Key Points

    Key Points • Well-understood mechanism (anti-angiogenesis) but unique differentiating feature (VEGFR3 selectivity) • Very strong preclinical data package, with evidence of activity in multiple tumors and favourable toxicology • High potential for combination use with immuno- oncology therapies • ‘Cl

  36. Slide 36: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (August 2021) on 6ix